KR20140032346A - 암의 치료/전이의 억제 - Google Patents
암의 치료/전이의 억제 Download PDFInfo
- Publication number
- KR20140032346A KR20140032346A KR1020137012365A KR20137012365A KR20140032346A KR 20140032346 A KR20140032346 A KR 20140032346A KR 1020137012365 A KR1020137012365 A KR 1020137012365A KR 20137012365 A KR20137012365 A KR 20137012365A KR 20140032346 A KR20140032346 A KR 20140032346A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- cancer
- ranolazine
- block
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 68
- 201000011510 cancer Diseases 0.000 title claims abstract description 49
- 230000005764 inhibitory process Effects 0.000 title abstract description 4
- 238000011282 treatment Methods 0.000 title description 40
- 206010027476 Metastases Diseases 0.000 title description 11
- 230000009401 metastasis Effects 0.000 title description 11
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 claims abstract description 155
- 229960000213 ranolazine Drugs 0.000 claims abstract description 155
- 230000000694 effects Effects 0.000 claims abstract description 73
- 229940079593 drug Drugs 0.000 claims abstract description 68
- 239000003814 drug Substances 0.000 claims abstract description 68
- 238000000034 method Methods 0.000 claims abstract description 45
- 230000001052 transient effect Effects 0.000 claims abstract description 20
- 230000002459 sustained effect Effects 0.000 claims abstract description 19
- 230000008883 metastatic behaviour Effects 0.000 claims abstract description 17
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims abstract description 14
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims abstract description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 25
- 208000026310 Breast neoplasm Diseases 0.000 claims description 25
- 206010060862 Prostate cancer Diseases 0.000 claims description 21
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 21
- 230000035755 proliferation Effects 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 10
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims description 4
- 230000002085 persistent effect Effects 0.000 claims description 3
- 229960004181 riluzole Drugs 0.000 claims description 3
- 230000004899 motility Effects 0.000 abstract description 26
- 230000005012 migration Effects 0.000 abstract description 23
- 238000013508 migration Methods 0.000 abstract description 23
- 230000006399 behavior Effects 0.000 abstract description 8
- 230000001394 metastastic effect Effects 0.000 abstract description 7
- 206010061289 metastatic neoplasm Diseases 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 2
- 230000001413 cellular effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 363
- 206010021143 Hypoxia Diseases 0.000 description 108
- 230000001146 hypoxic effect Effects 0.000 description 86
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 85
- 229910052760 oxygen Inorganic materials 0.000 description 85
- 239000001301 oxygen Substances 0.000 description 85
- 238000002474 experimental method Methods 0.000 description 66
- 238000003556 assay Methods 0.000 description 27
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 24
- 230000033001 locomotion Effects 0.000 description 23
- 230000007954 hypoxia Effects 0.000 description 22
- 231100000673 dose–response relationship Toxicity 0.000 description 21
- 239000013068 control sample Substances 0.000 description 20
- 238000005259 measurement Methods 0.000 description 19
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 18
- 229950010357 tetrodotoxin Drugs 0.000 description 18
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 18
- 230000001419 dependent effect Effects 0.000 description 16
- 230000012010 growth Effects 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 230000009545 invasion Effects 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 238000002203 pretreatment Methods 0.000 description 9
- 230000035899 viability Effects 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 8
- 108010082117 matrigel Proteins 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 230000021164 cell adhesion Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 208000037819 metastatic cancer Diseases 0.000 description 5
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 5
- 238000007781 pre-processing Methods 0.000 description 5
- 208000011581 secondary neoplasm Diseases 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000012909 foetal bovine serum Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 101000694017 Homo sapiens Sodium channel protein type 5 subunit alpha Proteins 0.000 description 3
- 102000018674 Sodium Channels Human genes 0.000 description 3
- 108010052164 Sodium Channels Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000003235 crystal violet staining Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100027198 Sodium channel protein type 5 subunit alpha Human genes 0.000 description 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000003352 cell adhesion assay Methods 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960003404 mexiletine Drugs 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 230000007959 normoxia Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2010/001908 WO2012049440A1 (en) | 2010-10-13 | 2010-10-13 | Treatment of cancer/inhibition of metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140032346A true KR20140032346A (ko) | 2014-03-14 |
Family
ID=44022817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137012365A Withdrawn KR20140032346A (ko) | 2010-10-13 | 2010-10-13 | 암의 치료/전이의 억제 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20130203764A1 (enExample) |
| EP (4) | EP2627321A1 (enExample) |
| JP (1) | JP2013539778A (enExample) |
| KR (1) | KR20140032346A (enExample) |
| CN (2) | CN103370060A (enExample) |
| AU (2) | AU2010362412A1 (enExample) |
| BR (1) | BR112013009086A2 (enExample) |
| CA (1) | CA2851694C (enExample) |
| DK (1) | DK3132791T3 (enExample) |
| IL (1) | IL225689A0 (enExample) |
| RU (1) | RU2013121744A (enExample) |
| SG (1) | SG189352A1 (enExample) |
| WO (1) | WO2012049440A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2013121744A (ru) | 2010-10-13 | 2014-11-20 | Мустафа Билгин Али ДЖАМГОЗ | Лечение рака/ингибирование метастазирования |
| WO2013123403A1 (en) * | 2012-02-15 | 2013-08-22 | Sanford-Burnham Medical Research Institute | Theranostics platform and methods of use |
| WO2017091574A1 (en) * | 2015-11-25 | 2017-06-01 | Health Research, Inc. | Riluzole and riluzole drug combinations for the treatment of prostate cancer |
| JP6465306B2 (ja) * | 2016-02-04 | 2019-02-06 | セレックス・オンコロジー・リミテッド | 癌の治療／転移の阻害 |
| IL292302B2 (en) * | 2016-05-20 | 2023-10-01 | Biohaven Pharm Holding Co Ltd | Use of glutamate modulating factors in cancer immunotherapy |
| CN110662545A (zh) * | 2017-02-10 | 2020-01-07 | 赛立斯肿瘤学创新有限公司 | 癌症治疗和转移抑制 |
| US20200123544A1 (en) * | 2018-10-22 | 2020-04-23 | Celex Oncology Innovations Limited | Gene therapy targeting the neonatal form of nav1.5 for treating cancer |
| WO2021078987A1 (en) | 2019-10-24 | 2021-04-29 | Celex Oncology Innovations Limited | Combination treatments for cancer |
| US12624101B2 (en) | 2020-01-21 | 2026-05-12 | Celex Oncology Innovations Limited | Monoclonal antibodies against neonatal Nav1.5 |
| US20230139204A1 (en) | 2020-03-09 | 2023-05-04 | Celex Oncology Innovations Limited | Measuring electric activity of cells for the evaluation of metastatic potential of cancer cells |
| WO2022005228A1 (ko) * | 2020-07-01 | 2022-01-06 | 국립암센터 | 3-케토아실 coa 타이올레이스 억제제 및 카르니틴 아실카르니틴 운반자 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물 |
| WO2025078664A1 (en) | 2023-10-12 | 2025-04-17 | Celex Oncology Innovations Limited | Treatment of metastatic or invasive brain cancer |
| WO2025252860A1 (en) | 2024-06-04 | 2025-12-11 | Celex Oncology Innovations Limited | Ranolazine enantiomer for use in cancer treatment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1659136A (zh) * | 2002-04-18 | 2005-08-24 | 弗吉尼亚大学专利基金会 | 新的钠通道阻滞剂 |
| CA2513399A1 (en) * | 2003-01-10 | 2004-07-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
| US8835473B2 (en) * | 2004-04-16 | 2014-09-16 | Rutgers, The State University Of New Jersey | Methods and compositions for treating cancer |
| US9018222B2 (en) | 2006-03-27 | 2015-04-28 | Wex Medical Limited | Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy |
| US8394377B2 (en) * | 2008-02-21 | 2013-03-12 | The Regents Of The University Of Colorado | Methods for treating cancer using combination therapy |
| US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
| US20110251144A1 (en) * | 2008-09-16 | 2011-10-13 | Massachusetts Institute Of Technology | Molecular modulators of the wnt/beta-catenin pathway |
| RU2013121744A (ru) | 2010-10-13 | 2014-11-20 | Мустафа Билгин Али ДЖАМГОЗ | Лечение рака/ингибирование метастазирования |
-
2010
- 2010-10-13 RU RU2013121744/15A patent/RU2013121744A/ru not_active Application Discontinuation
- 2010-10-13 CN CN2010800703488A patent/CN103370060A/zh active Pending
- 2010-10-13 EP EP10776791.5A patent/EP2627321A1/en not_active Withdrawn
- 2010-10-13 AU AU2010362412A patent/AU2010362412A1/en not_active Abandoned
- 2010-10-13 US US13/879,146 patent/US20130203764A1/en not_active Abandoned
- 2010-10-13 WO PCT/GB2010/001908 patent/WO2012049440A1/en not_active Ceased
- 2010-10-13 JP JP2013533265A patent/JP2013539778A/ja active Pending
- 2010-10-13 BR BR112013009086A patent/BR112013009086A2/pt not_active IP Right Cessation
- 2010-10-13 KR KR1020137012365A patent/KR20140032346A/ko not_active Withdrawn
- 2010-10-13 CN CN202110087549.9A patent/CN112755029A/zh active Pending
- 2010-10-13 SG SG2013026968A patent/SG189352A1/en unknown
- 2010-10-13 EP EP19211429.6A patent/EP3653206A1/en not_active Ceased
- 2010-10-13 EP EP16020321.2A patent/EP3132791B1/en active Active
- 2010-10-13 CA CA2851694A patent/CA2851694C/en active Active
- 2010-10-13 EP EP25174138.5A patent/EP4640281A3/en active Pending
- 2010-10-13 DK DK16020321.2T patent/DK3132791T3/da active
-
2013
- 2013-04-10 IL IL225689A patent/IL225689A0/en unknown
-
2015
- 2015-10-13 US US14/881,952 patent/US20160096812A1/en not_active Abandoned
-
2017
- 2017-04-06 AU AU2017202267A patent/AU2017202267B2/en active Active
-
2018
- 2018-06-07 US US16/002,555 patent/US20180346431A1/en not_active Abandoned
-
2019
- 2019-09-19 US US16/576,178 patent/US11634398B2/en active Active
-
2022
- 2022-12-19 US US18/068,263 patent/US12534444B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230202994A1 (en) | 2023-06-29 |
| AU2010362412A1 (en) | 2013-05-30 |
| US11634398B2 (en) | 2023-04-25 |
| BR112013009086A2 (pt) | 2016-07-26 |
| EP4640281A2 (en) | 2025-10-29 |
| EP3132791B1 (en) | 2019-11-27 |
| WO2012049440A1 (en) | 2012-04-19 |
| EP4640281A3 (en) | 2026-01-07 |
| AU2017202267B2 (en) | 2019-01-24 |
| US20160096812A1 (en) | 2016-04-07 |
| DK3132791T3 (da) | 2020-03-09 |
| RU2013121744A (ru) | 2014-11-20 |
| IL225689A0 (en) | 2013-06-27 |
| CN112755029A (zh) | 2021-05-07 |
| US20130203764A1 (en) | 2013-08-08 |
| CA2851694C (en) | 2019-02-26 |
| EP3653206A1 (en) | 2020-05-20 |
| US12534444B2 (en) | 2026-01-27 |
| CA2851694A1 (en) | 2012-04-19 |
| US20200017457A1 (en) | 2020-01-16 |
| EP2627321A1 (en) | 2013-08-21 |
| EP3132791A1 (en) | 2017-02-22 |
| SG189352A1 (en) | 2013-05-31 |
| JP2013539778A (ja) | 2013-10-28 |
| US20180346431A1 (en) | 2018-12-06 |
| AU2017202267A1 (en) | 2017-04-27 |
| CN103370060A (zh) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12534444B2 (en) | Treatment of cancer/inhibition of metastasis | |
| US20220125800A1 (en) | Treatment of cancer and inhibition of metastasis | |
| US8790925B2 (en) | Methods of generating hyper iNOS expressing cells and uses thereof | |
| Sun et al. | Preconditioning of mesenchymal stem cells with ghrelin exerts superior cardioprotection in aged heart through boosting mitochondrial function and autophagy flux | |
| JP2019001826A (ja) | 癌の治療／転移の阻害 | |
| JP6465306B2 (ja) | 癌の治療／転移の阻害 | |
| WO2012049439A1 (en) | Treatment of cancer/inhibition of metastasis | |
| JP2025010391A (ja) | 癌の治療／転移の阻害 | |
| GB2484513A (en) | Treatment of cancer/inhibition of metasesis using ranolazine or riluzole | |
| Salmon | A Tissue-Engineered Blood Vessel Model for Vascular Aging | |
| Ruscic et al. | Selective Activation of NaV1. 3 Restores Lymphatic Contractility in Age and Injury | |
| Saymeh | TELMISARTAN INHIBITS MELANOMA GROWTH AND METASTASIS THROUGH LRP1 SUPPRESSION | |
| Fakih | Molecular insights into pigmentation defects in xeroderma pigmentosum type C | |
| Cruz et al. | 118 NGF-INDUCE DETRUSOR OVERACTIVITY IS TRPV1 DEPENDENT | |
| Yokovama et al. | 117 EFFECTS OF ENCEPHALIN GENE THERAPY USING HERPES SIMPLEX VIRUS VECTOR ON BLADDER HYPERACTIVITYAND NOCICEPTION | |
| Park et al. | 116 ARE CLINICALLY INSIGNIFICANT PROSTATE CANCERS REALLY INSIGNIFICANT IN THE KOREAN POPULATION? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20130513 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |